New GLP-1/amylin agonist shows promise for blood sugar and weight

Researchers just published a comment in The Lancet on a novel unimolecular agonist targeting both GLP-1 and amylin receptors. This new compound is designed for glucose and weight control, pushing beyond single-hormone treatments for type 2 diabetes and obesity. It suggests a future where metabolic treatments hit more points in the body at once.